NRXS
Neuraxis, INC
NASDAQ · Healthcare · Biotechnology · US
$7.61
−0.26%Year over year
Reported trailing growth
- Revenue
- +65.2%
- EBITDA
- -7.0%
- EBIT
- -7.7%
- EPS
- +26.0%
- Free cash flow
- +9.9%
- Operating cash flow
- +9.7%
Forward estimates
Based on analyst estimates
- Revenue
- +127.6%
- EBITDA
- -6.8%
- EPS
- +13.0%
Three-year CAGR
- Revenue
- +10.0%
- EBITDA
- +3.0%
- EBIT
- -9.4%
- Net income
- +5.4%
- EPS
- +22.1%
- Free cash flow
- -5.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026